NorgesInvestor

NorgesInvestor is an asset management group based in Oslo, Norway, founded in 1996. The firm is dedicated to creating strategic and financial value through a variety of investment activities. These include private equity investments in mature and growth companies, discretionary wealth management, and investments in listed securities. NorgesInvestor also engages in private equity secondaries, emphasizing active ownership. The firm targets a diverse range of sectors, including telecommunications, information technology, retail, alternative energy, oil services, and manufacturing, primarily within Norway and Sweden. As a privately-owned and financially solid entity, NorgesInvestor maintains offices in both Oslo and Stockholm.

Jan Gunnar Hartvig

Founding Partner and CEO

Inge Hellebust

Partner, NorgesInvestor Formuesforvaltning

1 past transactions

Algeta

Series A in 2005

Algeta ASA, an oncology company, focused on developing targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Its lead product includes radium-223 dichloride, which completed Phase III clinical trial to treat castration-resistant prostate cancer with bone metastases. The company is also developing alpha-emitter thorium-227 that is in the preclinical phase linked to tumor-targeting molecules to form targeted thorium conjugates. It has an agreement with Bayer Pharma AG for the development and commercialization of radium-223 worldwide. The company was formerly known as Anticancer Therapeutic Inventions AS and changed its name to Algeta ASA in 2003. Algeta ASA was founded in 1997 and is headquartered in Oslo, Norway.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.